Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
Clindamycin Versus Amoxicillin With Clavulanic Acid in Prevention of Early Dental Implants Failure
- Conditions
- Antibiotics Causing Adverse Effects in Therapeutic Use
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Jordan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04980170
- Locations
- 🇯🇴
The University of Jordan Hospital, Amman, Jordan
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
- Conditions
- Pediatric Respiratory DiseasesAntibiotic UseCommunity-acquired PneumoniaPneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-02-15
- Target Recruit Count
- 5
- Registration Number
- NCT04963764
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Outcome of Patients After a Negative Oral Challenge to Amoxicillin
- Conditions
- Negative Challenge to Amoxicillin
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 190
- Registration Number
- NCT04922034
- Locations
- 🇫🇷
CHU, Angers, Maine Et Loire, France
Oral Amoxicillin and Cephalexin PK/PD in Neonates
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT04916951
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 234
- Registration Number
- NCT04907747
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 1300
- Registration Number
- NCT04901117
- Locations
- 🇨🇳
Qilu hosipital, Jinan, Shandong, China
Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Drug: Tetracycline,Metronidazole
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 413
- Registration Number
- NCT04879992
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
- Conditions
- Helicobacter Pylori
- Interventions
- Drug: Amoxicillin,Furazolidone and Vonoprazan fumarateDrug: Tetracycline,Furazolidone and Vonoprazan fumarateDrug: Amoxicillin,Levofloxacin and Vonoprazan fumarate
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 820
- Registration Number
- NCT04810793
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study of Vonoprazan in Adults With Helicobacter Pylori
- Conditions
- Helicobacter Pylori
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 44
- Registration Number
- NCT04753437
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China
Antibiotic PRophylAxis Based on infeCTIve Risk in Cardiac Implantable Electronic Device
- Conditions
- Device Related Infection
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- University Hospital of Ferrara
- Target Recruit Count
- 1044
- Registration Number
- NCT04736979
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.